Logo
x

Search

Subscribe Now

Chronic Lymphocytic Leukaemia

Roche Reports Long-Term Benefits of Venclexta/Venclyxto Based Combination for R/R Chronic Lymphocytic Leukemia

Roche Reports Long-Term Benefits of Venclexta/Venclyxto Based Combination for R/R Chronic Lymphocytic Leukemia

  • December 7, 2020
AstraZeneca's Calquence (acalabrutinib) Receives EU's Approval for Chronic Lymphocytic Leukaemia

AstraZeneca's Calquence (acalabrutinib) Receives EU's Approval for Chronic Lymphocytic Leukaemia

  • November 10, 2020
Janssen's Imbruvica (ibrutinib) + Rituximab Receives the EC's Marketing Authorization for Previously Untreated Patients with Chronic Lymphocytic Leukemia

Janssen's Imbruvica (ibrutinib) + Rituximab Receives the EC's Marketing Authorization for Previously Untreated Patients with Chron...

  • September 8, 2020
AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukaemia (CLL) in Adults

AstraZeneca's Calquence (acalabrutinib) Receives the US FDA's Breakthrough Therapy Designation to Treat Chronic Lymphocytic Leukae...

  • August 14, 2019
Janssen's Imbruvica (ibrutinib) Receives CHMP Positive Recommendation for its Expanded Use in Chronic Lymphocytic Leukaemia and Waldenstrom's Macroglobulinemia in Europe

Janssen's Imbruvica (ibrutinib) Receives CHMP Positive Recommendation for its Expanded Use in Chronic Lymphocytic Leukaemia and Wa...

  • July 1, 2019
AstraZeneca’s Calquence (acalabrutinib) Receives the US FDA’s Approval for the Treatment of Blood Cancers

    AstraZeneca’s Calquence (acalabrutinib) Receives the US FDA’s Approval for the Treatment of Blood Cancers

    • August 5, 2022
    Janssen’s Imbruvica (ibrutinib) Receives EC’s Approval as a Fixed-Duration Combination Regimen for Chronic Lymphocytic Leukaemia

      Janssen’s Imbruvica (ibrutinib) Receives EC’s Approval as a Fixed-Duration Combination Regimen for Chronic Lymphocytic Leukaemia

      • August 4, 2022
      AstraZeneca Presents Results of Calquence (acalabrutinib) in P-III (ELEVATE-TN) Trial as 1L Treatment of Chronic Lymphocytic Leukaemia at ASCO 2022

        AstraZeneca Presents Results of Calquence (acalabrutinib) in P-III (ELEVATE-TN) Trial as 1L Treatment of Chronic Lymphocytic Leuka...

        • June 6, 2022
        AstraZeneca Presents Results of Calquence in the P-III (ASCEND) Trial for the Treatment of Chronic Lymphocytic Leukaemia at ASH 2021

          AstraZeneca Presents Results of Calquence in the P-III (ASCEND) Trial for the Treatment of Chronic Lymphocytic Leukaemia at ASH 20...

          • December 13, 2021
          Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia

            Janssen Reports Long-Term Benefits of Imbruvica (ibrutinib) as 1L Treatment for High-Risk Chronic Lymphocytic Leukemia

            • December 7, 2020
            Roche Reports Long-Term Benefits of Venclexta/Venclyxto Based Combination for R/R Chronic Lymphocytic Leukemia

              Roche Reports Long-Term Benefits of Venclexta/Venclyxto Based Combination for R/R Chronic Lymphocytic Leukemia

              • December 7, 2020
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.